Press Releases

Apr 23, 2020
Bicycle Therapeutics Appoints Zafar Qadir as General Counsel
CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--Apr. 23, 2020-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced the appointment of Zafar
Apr 07, 2020
Bicycle Therapeutics Announces Pipeline Progress Update
- Phase I dose escalation completed for BT1718 — RP2D established and preliminary signs of anti-tumor activity observed, including one partial response - Dosing complete in second cohort of Phase I dose escalation for BT5528 — all doses administered in Phase I to date appear tolerable - Significant
Displaying 11 - 18 of 18